News

A child who was not vaccinated succumbed to measles pulmonary failure. Additionally, increased cases and hospitalizations continue to grow greatly in the state.

One hospital related the evolution of resistant Acinetobacter baumannii and Pseudomonas aeruginosa in its ICU to the COVID-19 pandemic.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies.

Patients with suspected sepsis in the emergency department are twice as likely to survive at 28 days when antibiotics are started within 1 hour.

Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.

Andrew Aronsohn, MD, associate professor of Medicine, University of Chicago Medical Center, discusses the hepatitis C (HCV) screen and treat plan that looks to utilize a one visit approach to get people tested and on medication in the same patient encounter.

Sharmeen Roy, PharmD, BCPS, discusses the role of AI, real-world evidence, and clinician oversight in optimizing medication dosing for ICU patients.

Lumen Bioscience’s LMN-201 was considered safe and well tolerated, and there were no severe dose-related or serious adverse events reported.

Indwelling devices and previous antibiotic exposure increased the risk for these infections.

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.

Ohio is now dealing with an outbreak, and the Centers for Disease Control and Prevention (CDC) reports nearly 500 total cases in the US.

Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.

Clinical-stage company, BiomX, said its therapy, BX211, was found to be safe and efficacious for this infection that was associated with Staphylococcus aureus.

Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.

The organization's reports discuss the small number of newly approved treatments, the limited, late-stage antifungal pipeline, and challenges around diagnostics for this class of infections.

Ashraf S. Ibrahim, PhD, details over 20 years of research on a spore-coating protein and the development of VX-01 to block fungal tissue invasion.

Ashraf S. Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.

New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.

Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president, discusses the potential implications these layoffs will have on clinicians and overall public health.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

The Visby Medical Women’s Sexual Health Test can screen for chlamydia, gonorrhea, and trichomoniasis.

This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.

Pamela Kushner, MD, offers insights on the newly approved antibiotic including its novel mechanism of action, the new criteria incorporated into the phase 3 studies, and what it means for her to have this treatment available.

The department is set to lay off 10,000 full-time employees, and with combined efforts, expects the reduction to be a total downsizing of 20,000 employees.

In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.

The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.

Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.